Oscar Health's Stock Rallies on 2026 Guidance as Trading Volume Surges to 397th in U.S. Rankings

Market Snapshot

Oscar Health (OSCR) rose 1.74% on February 10, 2026, as trading volume surged to $0.35 billion—a 82.15% increase from the prior day—ranking the stock 397th in volume among U.S. equities. The upward momentum followed the company’s Q4 2025 earnings report and its optimistic 2026 guidance, which outperformed analyst expectations despite challenges in its Obamacare plans.

Key Drivers

Oscar Health’s stock rally was primarily fueled by its 2026 revenue and earnings projections, which significantly exceeded consensus estimates. The company forecasted $18.7 billion to $19.0 billion in revenue for 2026, a 61% year-over-year increase, and projected operating earnings of $250 million to $450 million—far above the $12.8 billion consensus revenue. CEO Mark Bertolini emphasized that 2025 was a “reset year” for the individual health insurance market, with strategic actions taken to restore profitability. The guidance highlighted record membership growth, including 3.4 million members at the end of open enrollment, and anticipated AI-driven operational efficiencies.

However, Q4 2025 results underscored near-term challenges. The company reported a $1.24 GAAP loss per share on $2.8 billion in revenue, missing consensus by $310 million. Operating losses widened to $396.4 million in 2025, compared to $57.3 million in operating income in 2024, driven by a deteriorated medical loss ratio (MLR) of 87.4%—up from 81.7% the prior year. CFO Richard Blackley attributed this to elevated market morbidity in 2025 and incremental cost pressures in 2026. Despite these hurdles, Oscar projected a 450-basis-point improvement in MLR to 82.4%–83.4% for 2026, surpassing the 85.4% analyst forecast.

The company also faced headwinds from higher premiums and regulatory shifts. The expiration of enhanced premium tax credits post-pandemic has led to steeper rate hikes for Obamacare plans, with a 28% weighted average increase in 2026. While per-member-per-month costs were lower due to shifts in member demographics and plan tiers, CFO Blackley warned of elevated churn rates. CMS initiatives further complicated retention efforts, as members grapple with affordability concerns. Additionally, risk adjustment accruals—used to estimate future medical costs—created earnings headwinds in 2025 and are expected to remain elevated in 2026.

Investor sentiment was further shaped by Oscar’s stock volatility and institutional activity. Shares surged 4.8% initially after the earnings report but settled at a 4.1% gain. The stock has declined 12% year-to-date, trading 41.3% below its 52-week high. Recent institutional sales, such as Blue Square Asset Management’s full exit from its stake, raised concerns about near-term confidence. However, the 2026 outlook, coupled with membership growth and AI efficiencies, appears to have outweighed these worries, as analysts noted the market viewed the news as meaningful but not transformative.

Oscar’s ability to balance aggressive growth with profitability remains critical. While the 2026 guidance signals optimism in its membership base and cost management, the company must navigate a challenging regulatory environment and member retention pressures. The projected MLR improvements and operating earnings suggest a path to profitability, but execution risks—such as unexpected cost inflation or regulatory changes—could test investor confidence in the coming quarters.